Literature DB >> 10514290

Synthesis and antimicrobial activity of 4H-4-oxoquinolizine derivatives: consequences of structural modification at the C-8 position.

Z Ma1, D T Chu, C S Cooper, Q Li, A K Fung, S Wang, L L Shen, R K Flamm, A M Nilius, J D Alder, J A Meulbroek, Y S Or.   

Abstract

The antibacterial 4H-4-oxoquinolizines were introduced recently to overcome bacterial resistance to fluoroquinolones. They exhibit potent antibacterial activity against Gram-positive, Gram-negative, and anaerobic organisms and are highly active against some quinolone-resistant bacteria including quinolone-resistant MRSA. Preliminary studies indicated that oxoquinolizines possess distinct activity and toxicity profiles as compared with their parent quinolones. In order to develop a potent antibacterial agent with the desired spectrum of activity, good tolerability, and balanced pharmacokinetic profile, we synthesized and evaluated a series of oxoquinolizines with various substituents at the C-8 position. Most compounds tested in this study demonstrated better activity against Gram-positive bacteria than ciprofloxacin and exhibited good susceptibility against ciprofloxacin- and methicillin-resistant S. aureus. While maintaining potent in vitro activity, several compounds showed improved in vivo efficacy over ABT-719 as indicated by the mouse protection test. As an example, the oral ED(50) values for the cis-3-amino-4-methylpiperidine analogue 3ss against S. aureus NCTC 10649M, S. pneumoniae ATCC 6303, and E. coli JUHL were 0. 8, 2.0, and 1.4 mg/kg, compared to 3.0, 10.0, and 8.3 mg/kg for ABT-719. The current study revealed that the steric and electronic environment, conformation, and absolute stereochemistry of the C-8 group are very important to the antibacterial profiles. Structural modifications of the C-8 group provide a useful means to improve the antibacterial activities, physicochemical properties, and pharmacokinetic profiles. Manipulation of the C-8 group also allows us to generate analogues with the desired spectrum of activity, such as analogues that are selective against respiratory pathogens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514290     DOI: 10.1021/jm990191k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Physiological and transcriptomic responses of Chlorella sorokiniana to ciprofloxacin reveal molecular mechanisms for antibiotic removal.

Authors:  Zhuo Li; Shuangxi Li; Tianrui Li; Xinxin Gao; Liandong Zhu
Journal:  iScience       Date:  2022-06-18

Review 2.  Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules.

Authors:  Joanna Fedorowicz; Jarosław Sączewski
Journal:  Monatsh Chem       Date:  2018-06-07       Impact factor: 1.451

3.  A New Synthetic Route to Polyhydrogenated Pyrrolo[3,4-b]pyrroles by the Domino Reaction of 3-Bromopyrrole-2,5-Diones with Aminocrotonic Acid Esters.

Authors:  Khidmet Shikhaliev; Artem Sabynin; Valeri Sekirin; Michael Krysin; Fedor Zubkov; Kristina Yankina
Journal:  Molecules       Date:  2017-11-22       Impact factor: 4.411

4.  Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.

Authors:  Aleksey I Gerasyuto; Michael A Arnold; Jiashi Wang; Guangming Chen; Xiaoyan Zhang; Sean Smith; Matthew G Woll; John Baird; Nanjing Zhang; Neil G Almstead; Jana Narasimhan; Srinivasa Peddi; Melissa Dumble; Josephine Sheedy; Marla Weetall; Arthur A Branstrom; J V N Prasad; Gary M Karp
Journal:  J Med Chem       Date:  2018-05-14       Impact factor: 7.446

5.  GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens.

Authors:  Jeffry D Shearer; Michelle L Saylor; Christine M Butler; Anthony M Treston; Henry S Heine; Sunisa Chirakul; Herbert P Schweizer; Arnold Louie; George L Drusano; Steven D Zumbrun; Kelly L Warfield
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.